Morgan Stanley analyst Terence Flynn has maintained a Hold rating on Amgen (AMGN), setting a price target of $332.00. Flynn covers the healthcare sector and specializes in stocks such as BioNTech SE, Biogen, and Vertex Pharmaceuticals; according to TipRanks data, his average return is 8.7%...
On Friday, the Dow Jones Industrial Average closed down 52 points, or 0.1%, at 49,599, according to FactSet data. While the index showed a mixed performance with some components advancing, notably Apple, significant losses from Amgen and McDonald's weighed heavily on the overall gauge. Despite...
On April 30, 2026, Amgen (NASDAQ: AMGN) released corrected financial results for the first quarter of 2026, following an initial notice regarding changes to a previous announcement from Thousand Oaks, California. CEO Robert A. Bradway highlighted that the company's 16 brands achieved double-digit growth during...
Amgen (AMGN) significantly exceeded Wall Street expectations for its first-quarter financial results, a performance driven largely by robust sales of its cholesterol drug Repatha. The company reported adjusted earnings of $5.15 per share, a 5% increase compared to the previous year, which surpassed analyst forecasts...
Amgen Inc. (AMGN) reported its Q1 earnings for the quarter ended March 2026, posting quarterly earnings per share of $5.15, which exceeds the Zacks Consensus Estimate of $4.73. On an adjusted basis excluding non-recurring items, the company's earnings were $5.15, representing a significant year-over-year increase...
